Journal September 25, 2026 5 min read

What markers track time-restricted eating?

Time-restricted eating (TRE) is an eating-pattern intervention in which daily caloric intake is confined to a defined window. This page summarises the markers and outcomes measured in registered and published TRE researc

peptides-pro Editorial

Time-restricted eating (TRE) is an eating-pattern intervention in which all daily caloric intake is confined to a defined window, typically 10 hours or less, with the remaining hours constituting a fasting period. Synonyms include time-restricted feeding (TRF) and, in some protocols, chrono-nutrition or ChronoFeeding (CF). TRE is not a compound; it is a behavioural schedule, and the research literature therefore reports it through the physiological markers and clinical endpoints measured in the populations studied rather than through a molecular identifier such as a sequence, formula, or molecular weight.

The work centres on metabolic and circadian pathways, including insulin signalling, appetite-hormone regulation (leptin and adiponectin), inflammatory signalling (CRP, cortisol, sRAGE), and mitochondrial quality-control pathways such as autophagy and mitophagy.

Research Studies

TRE and appetite hormones, eating behaviour, and inflammatory markers in adults with obesity and prediabetes

The TRIM study was a 12-week randomised isocaloric and eucaloric feeding trial comparing 10-hour TRE to a 16-hour usual eating pattern (UEP) in adults with obesity and either prediabetes or diet-controlled type 2 diabetes. A post hoc analysis investigated TRE's effects on eating behaviour, appetite hormones, and inflammatory markers. Participants completed the Three-Factor Eating Questionnaire (Restraint, Disinhibition, Hunger) and provided fasting blood samples for leptin, adiponectin, CRP, cortisol, and sRAGE at pre- and post-intervention timepoints [1].

TRE and weight-loss maintenance in overweight or obese adults

A multi-centre, 2-arm randomised controlled trial across six regions in China is targeting overweight or obese adults who have recently achieved a short-term weight reduction of at least 5% of body weight. The trial evaluates whether a 10-hour daily TRE regimen more effectively prevents weight regain compared with standard weight maintenance counselling alone. Both groups receive the same frequency and intensity of nutritional counselling; the only difference is the TRE regimen [2].

TRE, GLP1 receptor agonists, and heart-healthy diet in prostate cancer patients during androgen deprivation therapy

The phase II IMPACT-ADT trial compares TRE and glucagon-like peptide-1 (GLP1) receptor agonists (semaglutide and tirzepatide) to an American Heart Association (AHA) heart-healthy diet (HHD) intervention in prostate cancer patients undergoing androgen deprivation therapy (ADT). The trial assesses effects on the cardiovascular system and on metabolic processing. Prostate cancer patients receiving ADT are at increased risk of cardiovascular disease, thought to be due to treatment-related metabolic changes that may result in increased weight, body fat, insulin resistance, and increased risk [3].

Urolithin A and mitochondrial, inflammatory, and metabolic markers during restricted eating in adults with obesity

A study will test whether daily Urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle programme (nutrition and sleep guidance); half receive Urolithin A and half a matching placebo. Background notes that weight loss can reduce skeletal muscle, especially in people with obesity, and that aging and obesity are both linked to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation. Urolithin A is described as a gut-derived, diet-related compound [4].

TRE and cardiometabolic risk markers in adult survivors of childhood cancer

A study will examine whether motivational sessions, including regular calls with a trained health coach, in combination with TRE is an effective way to achieve weight loss and lower cardiometabolic risk in adult survivors of childhood cancer. The intervention is compared with the usual approach of reviewing educational materials and measuring weight once a month. The study will not provide treatment for any disease or cancer [5].

TRE and glycaemic control, body composition, and cardiometabolic risk factors in type 2 diabetes

A 1-year study aims to investigate the effectiveness of a TRE-based intervention on glycaemic control, body weight and composition, cardiometabolic risk factors, and behaviour in individuals with overweight or obesity and type 2 diabetes (T2D) [6].

TRE and microbiome, inflammation, and oxidative stress markers in adults with ADHD

A randomised controlled pilot study of 60 adults diagnosed with ADHD, aged 18 to 65, who have extended eating habits (more than 14 hours a day) and sleep problems, will examine how an intervention based on TRE (ChronoFeeding or CF) affects quality of life, behaviour, sleep, and gut health. The study will also examine biological markers including microbiota (gut and saliva bacteria), inflammation, and oxidative stress, in both humans and animal models [7].

TRE and insulin markers in polycystic ovarian syndrome

Polycystic ovarian syndrome (PCOS) is associated with metabolic symptoms such as hyperinsulinaemia. A randomised controlled crossover trial will test the feasibility of TRE in the management of PCOS by means of a real-world clinical intervention, determining whether an 18:6 eating protocol reduces insulin levels [8].

Markers measured across TRE studies

Marker category	Specific markers	Population or model	Source
Appetite hormones	Leptin, adiponectin	Adults with obesity and prediabetes or diet-controlled T2D	[1]
Inflammatory markers	CRP, cortisol, sRAGE	Adults with obesity and prediabetes or diet-controlled T2D	[1]
Eating behaviour	Three-Factor Eating Questionnaire (Restraint, Disinhibition, Hunger)	Adults with obesity and prediabetes or diet-controlled T2D	[1]
Weight maintenance	Weight regain	Overweight or obese adults after ≥5% weight loss	[2]
Cardiometabolic and metabolic	Cardiovascular system, metabolic processing	Prostate cancer patients on ADT	[3]
Mitochondrial, inflammatory, metabolic	Mitochondrial health, inflammation, metabolism, functional muscle mass	Adults with obesity	[4]
Cardiometabolic risk	Weight loss, cardiometabolic risk	Adult survivors of childhood cancer	[5]
Glycaemic and body composition	Glycaemic control, body weight and composition, cardiometabolic risk factors, behaviour	Overweight or obesity with T2D	[6]
Microbiome, inflammation, oxidative stress	Gut and saliva microbiota, inflammation, oxidative stress	Adults with ADHD; animal models	[7]
Insulin	Serum insulin, insulin resistance	PCOS	[8]

If you are reading this for personal health reasons

The materials and interventions described here are for laboratory research and clinical investigation. We do not provide dosing or medical guidance. Anyone considering a compound or an eating intervention for themselves should speak to a licensed clinician.